TACSTD2 and breast carcinoma: Recent studies demonstrated that a humanized version of TROP2-specific monoclonal antibody (hRS7) labeled with a radioiodinated, diethylenetri-aminepentaacetic acid-appended peptide, 131I-IMP-R4, exhibited a desirable therapeutic effect in a breast cancer model in vivo [25].